Gossamer Bio, Inc.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company specializing in immunology, inflammation, and oncology therapeutics. The company's revenue is generated through the discovery, acquisition, development, and commercialization of various treatments. Its product pipeline includes GB002, an inhaled small molecule for pulmonary arterial hypertension; GB004, an oral small molecule for inflammatory bowel disease; GB5121, an oral inhibitor for primary central nervous system lymphoma; and GB7208, an oral BTK inhibitor for multiple sclerosis treatment.

Products

• GB002 for pulmonary arterial hypertension

• GB004 for inflammatory bowel disease

• GB5121 for primary central nervous system lymphoma

• GB7208 for multiple sclerosis